ACL Announces Launch of AdvoOnc™ Hereditary Cancer Testing

June 2026

Effective Wednesday, July 1, 2026, ACL Laboratories will begin performing the following hereditary cancer genetic testing options at ACL's Illinois Central Laboratory.

- AdvoOnc™ STAT Hereditary Breast Cancer Panel (Test Order Code LAB13131)
  - » For patients with an active breast cancer diagnosis who require expedited results to guide immediate treatment decisions, analysis of 10 genes, including *ATM, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, STK11, TP53,* will be performed with results expected in less than 7 days
  - » Providers must select one of the following concurrent testing panels for both timely and comprehensive evaluation
    - AdvoOnc™ Concurrent Common Hereditary Cancer Panel (32 additional genes)
    - AdvoOnc™ Concurrent Expanded Hereditary Cancer Panel (62 additional genes)
- AdvoOnc™ Hereditary Breast & Gyn Cancers Panel (Test Order Code LAB13117)
  - » Analyzes 19 genes; indicated for patients with a personal and/or family history limited to breast, ovarian, or uterine cancers
- AdvoOnc™ Common Hereditary Cancer Panel (Test Order Code LAB13119)
  - » Analyzes 42 genes; indicated for patients with a personal or family history of breast, ovarian, colorectal, uterine, pancreatic, renal, or stomach cancers
- Targeted familial testing for variants in hereditary cancer genes that have been reported by ACL
  - » AdvoTargeted™ Analysis SNV (Test Order Code LAB13153) - targeted analysis of single nucleotide variants
  - » AdvoTargeted™ Analysis CNV (Test Order Code LAB13154) - targeted analysis of copy number variants

Clinical Indications

- Cancer diagnosed at an early age (≤50 years)
- Multiple occurrences of the same or related cancer types within a family
- Rare cancer types (e.g., ovarian, pancreatic, or male breast cancer)
- Tumors with distinctive features (e.g., triple-negative breast cancer)
- Suspected germline variants identified through somatic tumor testing
- A known familial pathogenic variant associated with hereditary cancer
- Additional guidelines are available through the National Comprehensive Cancer Network (NCCN)

Test Methodology

- Next Generation Sequencing (NGS)

Specimen Requirements

- Preferred - One pink (K2EDTA) 6.0 mL OR Two lavender (K2EDTA) 3.0 mL
- Also accepted - One ORAcollect™ DX Buccal Swab kit or One Oragene™ DX Saliva kit (Available upon request. Contact an ACL Genetic Counselor at ACL-GeneticCounselors@aah.org)

continued »

Created: 6/2026 | Created by: J. Sok - ACL Molecular Pathology | Designed by: C. McDonough - Lively CM-HB-2606a

Supply Ordering

- ACL Outreach Clients can order these supplies through the online supply portal (NPN360)
- Internal ACL sites can obtain supplies using the below Workday information

Collection Kit	ORAcollect DX Buccal Swab	ORAgene DX Saliva
Workday Item #	3029385	3059266
Photo		

Transport

- 5.0 mL (minimum 1.0 mL) whole blood, refrigerated
- ORAcollect™ Dx Buccal Swab kit, ambient
- Oragene™ DX Saliva kit, ambient

Unacceptable Conditions

- Clotted or hemolyzed specimens, dependent on the level of hemolysis
- Specimens collected in anticoagulants other than K2EDTA
- Fresh or frozen tissue, FFPE tissue blocks, or slides
- Decalcified tissue
- Saliva or buccal swab samples not meeting collection requirements
- Blood is not accepted for patients with a history of recent blood transfusion or an allogenic bone marrow/stem cell transplant

Testing Schedule & Reporting

- Performed: Weekdays
- Performing Site: ACL Illinois Central Lab – Molecular Pathology
- Reporting Time: Breast STAT Final results within 7 days and Panels final with 21 days.

If you have any questions, please contact: ACL Molecular Pathology Laboratory at Rosemont (847.349.7182), or ACL Client Services (800.877.7016)

Created: 6/2026 | Created by: J. Sok - ACL Molecular Pathology | Designed by: C. McDonough - Lively
CM-HB-2606a